Organigram (OGI) Competitors

Sana Biotechnology (NASDAQ:SANA) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.

Is SANA or OGI more profitable?

Sana Biotechnology has a net margin of 0.00% compared to Organigram's net margin of -45.57%. Organigram's return on equity of -16.76% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-84.22%	-44.97%
Organigram	-45.57%	-16.76%	-14.32%

Does the MarketBeat Community believe in SANA or OGI?

Organigram received 181 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 70.71% of users gave Organigram an outperform vote while only 56.67% of users gave Sana Biotechnology an outperform vote.

Company	Underperform	Outperform
Sana Biotechnology	Outperform Votes 17 56.67%	Underperform Votes 13 43.33%
Organigram	Outperform Votes 198 70.71%	Underperform Votes 82 29.29%

Which has more volatility and risk, SANA or OGI?

Sana Biotechnology has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of SANA or OGI?

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 31.1% of Sana Biotechnology shares are owned by company insiders. Comparatively, 0.1% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has higher earnings & valuation, SANA or OGI?

Organigram has higher revenue and earnings than Sana Biotechnology. Organigram is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$283.26M	-$1.40	-1.85
Organigram	$161.08M	1.01	-$184.34M	-$0.42	-3.57

Do analysts rate SANA or OGI?

Sana Biotechnology presently has a consensus target price of $13.50, suggesting a potential upside of 421.24%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Organigram.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer SANA or OGI?

In the previous week, Sana Biotechnology had 12 more articles in the media than Organigram. MarketBeat recorded 13 mentions for Sana Biotechnology and 1 mentions for Organigram. Organigram's average media sentiment score of 1.89 beat Sana Biotechnology's score of 0.44 indicating that Organigram is being referred to more favorably in the news media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Organigram	Very Positive

Summary

Organigram beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks.